TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29985719
Drug: Sham BEMER
Normalized name: Beser
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sham BEMER treatment combined with rehabilitation
Study: 30971301
Drug: Definitive concurrent
Normalized name: ESIKA PRO HD COLOR HIGH DEFINITION COLOR SPF 20 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definitive concurrent chemoradiotherapy (DCRT) with intensity-modulated radiation therapy (IMRT) at 50 Gy/25 fractions and basic chemotherapy with 5-fluorouracil regimens
Study: 26115797
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (7.5 mg/kg every 3 weeks, continued with up to 12 further cycles)
Study: 26115797
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (in poor prognosis subgroup)
Study: 26115797
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (in poor prognosis subgroup)
Study: 26115797
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (in non-high-risk patients)
Study: 26115797
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (in non-high-risk patients)
Study: 22327088
Drug: Placebo (glucose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glucose: 30 mg·d⁻¹)
Study: 16102683
Drug: Propofol TCI
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol TCI (Diprifusor pharmacokinetic model) starting at 4 microg/mL, adjusted by 0.4 microg/mL step size
Study: 2860740
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg) plus placebo
Study: 6337428
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg) plus Persantine (75 mg) four times daily
Study: 17369904
Drug: Poetam (affinity‐purified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poetam (affinity‐purified antibodies to recombinant human erythropoietin) combined with iron preparation
Study: 17369904
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with Poetam
Study: 17369904
Drug: Sorbifer (iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbifer (iron preparation)
Study: 14669170
Drug: Pramlintide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (120 microg twice daily or 150 microg 3 times a day)
Study: 8830301
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg, p.o.)
Study: 110129
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids plus arginine and histidine infusion
Study: 30866485
Drug: Skate skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skate skin collagen peptides (SCP) 2000 mg per day for 12 weeks
Study: 16822117
Drug: Clinic-plus-Internet cognitive-behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-plus-Internet cognitive-behavior therapy
Study: 8344093
Drug: Bowel lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel lavage with polyethylene glycol electrolyte solution (Colyte) after 2 g acetaminophen dose
Study: 8344093
Drug: Bowel lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel lavage with polyethylene glycol electrolyte solution (Colyte) after 4 g acetaminophen dose
Study: 24245978
Drug: 1,064 nm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,064 nm Q-Switched Nd:YAG laser plus chemical peeling with Jessner's solution (Group B)
Study: 8669100
Drug: FK506 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK506 (0.2 mg/kg/day)
Study: 1839993
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fenoterol and ipratropium bromide (200 micrograms and 40 micrograms respectively)
Study: 28771918
Drug: Positive Psychology
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Psychology Intervention (PPI) followed by Cognitive Behavioural Therapy (CBT)
Study: 26103559
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with acid-etched surface combined with local application of melatonin gel at the osteotomy site
Study: 26103559
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with acid-etched surface
Study: 25050592
Drug: Oxycodone once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone once daily (OOD)
Study: 16674606
Drug: Oxcarbazepine 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine 1,200 mg/day
Study: 16674606
Drug: Oxcarbazepine 1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine 1,800 mg/day
Study: 16674606
Drug: Oxcarbazepine 600
Normalized name: oxcarbazepine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine 600 mg/day
Study: 15203576
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (IL) administered after meals
Study: 12468570
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg/d
Study: 27643171
Drug: Indapamide 1.5
Normalized name: indapamide 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1.5 mg/d
Study: 15757965
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg every 6 weeks up to week 156
Study: 12120881
Drug: Thiamphenicol glycinate
Normalized name: thiamphenicol glycinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamphenicol glycinate hydrochloride (TGH) 1500 mg daily for 10 days
Study: 12120881
Drug: Clarithromycin 1000
Normalized name: clarithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 1000 mg daily for 10 days
Study: 2125938
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (NIC) 500 mg with placebo
Study: 2125938
Drug: Acipimox (AC)
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (AC) 500 mg
Study: 2125938
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 1500 mg
Study: 7013865
Drug: L‐Asparaginase consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐Asparaginase consolidation
Study: 24321801
Drug: Beclometasone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclometasone 100 μg plus formoterol 6 μg as maintenance and reliever treatment
Study: 8682483
Drug: r‐IFN alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐IFN alpha‐2a (5 million units, subcutaneously, thrice weekly)
Study: 8682483
Drug: r‐IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐IFN alpha‐2b (5 million units, subcutaneously, thrice weekly)
Study: 6122694
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate (125 to 500 mg)
Study: 6122694
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate (500 mg)
Study: 31213771
Drug: 7% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% lidocaine aerosol (5 sprays, 22.5mg) sprayed into the tracheostomy incision (Group III)
Study: 30254189
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg once daily
Study: 28235523
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anesthesia (TIVA) with propofol-remifentanil
Study: 15901026
Drug: Inhaled anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anesthetic group (propofol-fentanyl-isoflurane)
Study: 11953965
Drug: Pyramid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyramid treatment strategy (initial NSAIDs, followed by chloroquine or sulfasalazine)
Study: 2172175
Drug: 200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg body weight FDP
Study: 419426
Drug: Povidone-iodine solution
Normalized name: POVIDONE-IODINE 1 g in 100 mL TOPICAL LIQUID [Loris Povidone-Iodine Solution]
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine solution irrigation
Study: 1731672
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution irrigation
Study: 16597655
Drug: Propofol 20
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 20 mg
Study: 10023283
Drug: Propofol 30
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 30 mg
Study: 19636533
Drug: Intermediate glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate glucose control (target BG 7.8-10.0 mmol/L)
Study: 17470885
Drug: Haloperidol 2
Normalized name: haloperidol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2 mg iv
Study: 17470885
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg iv
Study: 2889459
Drug: Bevantolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol (200 mg)
Study: 18996881
Drug: B-GOS (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-GOS (5.5 g/d)
Study: 12654764
Drug: ABT-773 (cethromycin)
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-773 (cethromycin) at a dose of 150 mg once a day for 10 days
Study: 12654764
Drug: ABT-773 (cethromycin)
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-773 (cethromycin) at a dose of 150 mg twice a day for 10 days
Study: 10218061
Drug: Sorbitol-sweetened sour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol-sweetened sour lemon lozenge
Study: 10218061
Drug: Sorbitol/xylitol-sweetened artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol/xylitol-sweetened artificial saliva substitute spray
Study: 8160944
Drug: Indomethacin suppositories
Normalized name: Indomethacin Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppositories 200 mg p.r. at the end of anaesthesia, followed by 100 mg bd for three days
Study: 17200359
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus trastuzumab
Study: 19255824
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 50 mg of losartan plus 12.5 mg of hydrochlorothiazide
Study: 19255824
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with 160 mg of valsartan
Study: 16421661
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral intake supplementation with a formula enriched with arginine, omega-3 fatty acids and ribonucleic acid for five days (supplemented group; n = 19)
Study: 15614033
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination of perindopril (2 mg) and indapamide (0.625 mg)
Study: 15614033
Drug: Stepped-care (valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care (valsartan 40 mg, valsartan 80 mg, hydrochlorothiazide 12.5 mg)
Study: 9404442
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy (0.125 iu/kg/week for the first month and 0.25 iu/kg/week for the following 5 months)
Study: 29676870
Drug: Thiazide-like diuretics
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide-like diuretics (e.g., chlorthalidone, indapamide)
Study: 20950882
Drug: External Beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Beam Radiation Therapy (EBRT)
Study: 24502859
Drug: Aripiprazole (2-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (2-15 mg/d)
Study: 17665078
Drug: 1% propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% propofol + 0.5 mg.ml‐1 ephedrine
Study: 15343012
Drug: Conventional intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional intensive care treatment (n = 20, controls)
Study: 11166779
Drug: Etofibrate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etofibrate (1 g per day for 1 month)
Study: 8148216
Drug: Cetirizine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 10 mg orally, 3 h before repeat nasal challenge with histamine
Study: 24666826
Drug: Half-molar sodium
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-molar sodium lactate infusion (3 ml/kg bolus over 15 minutes followed by 1 ml/kg/h continuous infusion for 24 hours)
Study: 24666826
Drug: Hartmann's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartmann's solution (3 ml/kg bolus without continuous infusion)
Study: 17911444
Drug: Bromocriptine (BRC)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (BRC) 2.5 mg/day and prednisone 10 mg/day
Study: 9525445
Drug: Prednisone 10
Normalized name: prednisone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 10 mg/day
Study: 23911057
Drug: Medication Recommendation
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Recommendation Tracking Form (MRTF)
Study: 24496960
Drug: Morphine dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine dosing algorithm (5 μg/kg(1.5)/h for neonates with PNA <10 days)
Study: 19464028
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol (RAC) 20 mg/hour
Study: 12105816
Drug: Cornstarch placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cornstarch placebo capsule for 90 days
Study: 7582389
Drug: Xylitol (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (10% solution, infused intravenously over 2 hours)
Study: 30650446
Drug: Apixaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (10 mg twice daily for 7 days, then 5 mg twice daily thereafter)
Study: 30650446
Drug: Enoxaparin/warfarin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin/warfarin (1 mg/kg twice daily for ≥ 5 days, followed by warfarin)
Study: 30650446
Drug: Apixaban (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (with anti-platelet therapy)
Study: 30650446
Drug: Enoxaparin/warfarin (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin/warfarin (with anti-platelet therapy)
Study: 18297268
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 25) treated by an implemented insulin algorithm
Study: 12702522
Drug: Vinorelbine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 20 mg/m(2) on days 1 and 8 (group 1)
Study: 12702522
Drug: Vinorelbine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 40 mg/m(2) on day 1 (group 3)
Study: 27451390
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg intravenously every 2 weeks)
Study: 29477448
Drug: Indacaterol (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol (110 μg) plus glycopyrronium (50 μg) once per day for 14 days
Study: 17989110
Drug: Pharmacogenetic-guided dosing
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetic-guided dosing
Study: 22534813
Drug: Injection dexamethasone
Normalized name: dexamethasone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection dexamethasone only (Control)
Study: 16470128
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 or 80 mg/day
Study: 15457423
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg for 7 days followed by 21 additional days of fondaparinux
Study: 11421879
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg b.d. (PAC 250)
Study: 11421879
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg b.d. (PAC 500)
Study: 10423636
Drug: Intravenous prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prostaglandin E1 (PGE1) infusion for 24 hours at a mean dosage of 16 +/- 3 ng/kg/min (range, 10-20 ng/kg/min)
Study: 10423636
Drug: Intravenous prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prostaglandin E1 (PGE1) infusion
Study: 10423636
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Group I)
Study: 1859751
Drug: Edrophonium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.5 mg kg‐1
Study: 27438317
Drug: Salsalate (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (3.5 g/d)
Study: 21899713
Drug: Ursodesoxycholic acid
Normalized name: Tauroursodesoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodesoxycholic acid (UDCA) 10 mg/kg orally per day for 24 months
Study: 21899713
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet for 24 months
Study: 9808231
Drug: Conventional dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dairy products (34 g lactose/d)
Study: 9808231
Drug: Lactose-hydrolyzed dairy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-hydrolyzed dairy products (2 g lactose/d)
Study: 12730476
Drug: Micronutrient supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplements
Study: 15215111
Drug: BAL5788 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL5788 at 750 mg
Study: 15607398
Drug: RSD-2 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSD-2 (2 mg/kg followed by 3 mg/kg)
Study: 12504938
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate 20 mg
Study: 3016226
Drug: Oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoclopramide (0.5 mg/kg/24 h)
Study: 3016226
Drug: Liquid alginic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid alginic acid‐antacid compound
Study: 31340982
Drug: Zanubrutinib 160
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 160 mg twice daily
Study: 12641480
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with an ACE inhibitor-based blood pressure-lowering regimen (perindopril) with or without indapamide
Study: 1998307
Drug: Diltiazem (60-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60-90 mg qid)
Study: 18657102
Drug: Framing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Framing of attributes (e.g., cancers found vs. cancers missed)
Study: 363479
Drug: amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amitriptyline 25 mg
Study: 31182062
Drug: Tablet-based intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-based intervention including a screening questionnaire for violence and a video on violence and safety behaviours.
Study: 15327617
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 400 microg every 3 hours for a maximum of five doses
Study: 15327617
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 400 microg every 3 hours for a maximum of five doses
Study: 9581985
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (150 mg caffeine)
Study: 11509481
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (<2 mg caffeine)
Study: 17456569
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 0.67 mg/d
Study: 14735126
Drug: Trihexyphenidyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trihexyphenidyl (1 mg)
Study: 14735126
Drug: Trihexyphenidyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trihexyphenidyl (2 mg)
Study: 28583162
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 mg/kg daily for 3 weeks)
Study: 26496361
Drug: Facilitated tucking
Normalized name: Tucks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated tucking with oral glucose
Study: 26496361
Drug: Oral water
Normalized name: Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral water (placebo)
Study: 26496361
Drug: Facilitated tucking
Normalized name: Tucks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated tucking with oral water
Study: 23369426
Drug: Both written
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both written and oral information modalities
Study: 23369426
Drug: Oral information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral information modality (presentation)
Study: 15292331
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg twice a day)